Conor Killmurray | Authors


FDA Requests Belantamab Mafodotin for R/R Multiple Myeloma Be Pulled From US Market

November 22, 2022

After an update from the phase 3 DREAMM-3 study the use of belantamab monotherapy for previously treated patients with relapsed or refractory multiple myeloma was pulled from US market authorization by request of the FDA.